Warts Management - Drug Doses & Treatment Options

Warts are caused by human papillomavirus (HPV). Management is guided by wart type (common, plantar, anogenital, flat), patient age/immune status, and prior treatment response. At least 3 months of sustained management is a reasonable therapeutic trial.

A. COMMON & PLANTAR WARTS

1. Destructive / Occlusive Therapy

Treatment	Dose / Protocol
Cryotherapy (liquid nitrogen)	Freeze to produce a blister; 30-45 sec thaw time for common warts; 10-sec sustained freeze with spray gun; repeat every 2-3 weeks
Salicylic acid (OTC 10-26%)	Soak area in water 5-10 min, apply, cover with strip bandage for 24 h; repeat daily; debride with pumice stone between applications
Cantharone (0.7% cantharidin)	Apply to wart, allow to dry, cover with occlusive tape for 24 h; blister forms in 24-72 h; repeat every 2-3 weeks
Silver nitrate	Applied topically (limited evidence); caution - risk of silver impregnation into skin

2. Immunologic / Immunotherapy

Treatment	Dose / Protocol
Oral cimetidine	25-40 mg/kg/day; used as adjunct; single-agent efficacy ~30% (comparable to placebo)
Topical sensitizers (DNCB, squaric acid dibutylester, diphencyprone)	Office: 2-5% in acetone, every 2 weeks; OR take-home: 0.2-0.5% daily; keep covered 24 h after application; 60-80% cure rate
Intralesional Candida antigen	0.1 mL injected into 1-3 lesions; repeat every 3-4 weeks; up to 80% cure rate
Oral zinc	Benefit only in zinc-deficient patients; limited by GI upset

3. Antiproliferative Therapy

Treatment	Dose / Protocol
Intralesional bleomycin	1 U/mL injected until wart blanches; small warts (<5 mm): 0.1 mL; larger warts: 0.2 mL; can use 0.1 U/mL with multipuncture technique; repeat every 3 weeks; typically 1-2 treatments needed; ~90% response rate
Topical 5-fluorouracil (5-FU)	Applied topically for recalcitrant or flat warts
Intralesional 5-FU	Used in refractory cases

Note: Bleomycin is reserved for recalcitrant warts in adults. Raynaud's phenomenon is a contraindication (risk of digital vasospasm/necrosis).

4. Surgical / Laser Options (for refractory warts)

Pulsed dye laser: fluence 12.5-15 J/cm2, spot size 7 mm, extend 2 mm beyond wart; every 2-4 weeks; 70-90% success in refractory warts
CO2 laser: 56-81% efficacy; scarring risk
Surgical excision, curettage: reserved for refractory cases

B. ANOGENITAL WARTS

Patient-Applied (Self-Administered)

Drug	Dose & Schedule
Imiquimod 3.75% cream	Once daily at bedtime; wash off after 6-10 hours; up to 16 weeks
Imiquimod 5% cream	Once at bedtime 3 times/week; wash off after 6-10 hours; up to 16 weeks
Podofilox (podophyllotoxin) 0.5% solution or gel	Apply twice daily for 3 days, then 4 days off = 1 cycle; up to 4 cycles; max 0.5 mL/day; total wart area must not exceed 10 cm2
Sinecatechins 15% ointment	Apply 3 times/day for up to 16 weeks; do NOT wash off after application

Provider-Administered

Treatment	Dose / Protocol
Cryotherapy (liquid nitrogen/cryoprobe)	Repeat every 1-2 weeks
Trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80-90%	Apply to wart, allow to dry before patient stands; if intense pain, neutralize with soap/water or sodium bicarbonate; repeat weekly
Surgical excision, electrocautery, curettage	Performed with local anesthesia

C. SPECIAL NOTES

Pregnancy-safe options: Cryotherapy, TCA/BCA, surgical excision. Podofilox and sinecatechins are contraindicated in pregnancy. Imiquimod has limited data (animal data suggests low risk).
Imiquimod side effects: erythema, irritation, ulceration, hypopigmentation; weakens latex condoms/diaphragms.
Sinecatechins should be avoided in immunocompromised patients.
Topical immunotherapy (DNCB, squaric acid, diphencyprone, Candida antigen) achieves 60-80% cure rates - comparable to destructive methods but less scar risk.

D. HPV VACCINATION (Prevention)

Dosage: 0.5 mL IM
Age <15 years: 2-dose schedule (0 and 6-12 months)
Age ≥15 years: 3-dose schedule (0, 1-2 months, and 6 months)
Immunocompromised (age 9-26): 3-dose schedule always

Sources:

Andrews' Diseases of the Skin - Clinical Dermatology
Campbell-Walsh-Wein Urology
Goldman-Cecil Medicine

Recent evidence note: A 2025 meta-analysis (PMID: 40873359) evaluated ionic contra-viral therapy (digoxin-furosemide) for multiple cutaneous warts - an emerging approach not yet in standard guidelines.

This is a shared conversation. Sign in to Orris to start your own chat.